Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum NeonMind Biosciences C.NEON

Alternate Symbol(s):  NMDBF

NeonMind Biosciences Inc is engaged in preclinical research to develop potential clinical treatments and wellness products to address obesity and weight management conditions and to promote health and wellness. The company operates three divisions: a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings; and a consumer products division that currently sells mushroom-infused products to promote health and wellness.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

𓋼🤑𓋼 Mushroom News ~ Roadmap for 2022 & Early 2023

Lobe is preparing a pre-IND meeting request with the US Food and Drug Administration (FDA) to confirm its regulatory strategy and Phase I clinical protocols. We expect to have this meeting in the 3rd& more

NeonMind To Improve Patient Care

Engages Thrive Health, a Leading Digital Patient Care Platform to Streamline Care Programs and Data Collection OAKVILLE, ON / ACCESSWIRE / April 21, 2022 / NeonMind Biosciences Inc. (CSE:NEON)( more

Neovasc Announces Direct Sales Operations in United Kingdom

Fred Colen, Neovasc President and Chief Executive Officer, said, “We are pleased to expand our direct presence into the United Kingdom and want to thank our partners at Healthcare 21 for their excellent foundational efforts supporting the early growth of Reducer. We are now poised to provide even deeper support with a full-time dedicated team in the U.K. and intend to continue to invest in clinical research and field personnel to support patients, physicians, and hospitals.” more

i did own this one sold last year

still looks like a bad investment  rate and reply

Addition of Mental Health Expert to Specialty Clinics Board  rate and reply